Contineum Therapeutics/$CTNM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
- Ticker
- $CTNM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 51
- Headquarters
- San Diego, United States
- Website
- www.contineum-tx.com
CTNM Metrics
BasicAdvanced
$313M
-
-$1.72
0.74
-
Price and volume
Market cap
$313M
Beta
0.74
52-week high
$17.79
52-week low
$6.73
Average daily volume
1.2M
Financial strength
Current ratio
37.171
Quick ratio
36.247
Long term debt to equity
0.017
Total debt to equity
0.027
Profitability
EBITDA (TTM)
-65.996
Management effectiveness
Return on assets (TTM)
-19.15%
Return on equity (TTM)
-28.01%
Valuation
Price to book
1.3
Price to tangible book (TTM)
1.3
Price to free cash flow (TTM)
-5.201
Free cash flow yield (TTM)
-19.23%
Free cash flow per share (TTM)
-1.598
Growth
Earnings per share change (TTM)
-21.76%
What the Analysts think about CTNM
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
Analyst projections of the future price of Contineum Therapeutics stock.
Bulls say / Bears say
Bristol Myers Squibb’s Phase 3 IPF result, with its 60 mg dose meeting the primary endpoint, offers human evidence that LPA1 blockade can work in this disease. That supports PIPE-791’s rationale, though it does not prove Contineum’s candidate will succeed. (Yahoo Finance)
In an exploratory 43-patient Phase 1b pain study, PIPE-791 was generally well tolerated and several pain measures numerically improved more than with placebo. This gives the drug a possible use beyond IPF, although larger trials must establish whether the effect is real. (Business Wire)
Contineum reported $236.6 million in cash and a projected runway through mid-2029, while more than 55 PROPEL-IPF trial sites were active across eight countries. This gives the company time to advance its main clinical programme without an immediate need to raise funds. (Contineum Therapeutics)
PIPE-307 failed to meet the primary endpoint in its Phase 2 depression trial. That weakens the value of a partnered programme that could otherwise have delivered milestone income to Contineum. (Reuters)
Contineum’s investment case now leans heavily on PIPE-791, which remains in a Phase 2 trial of about 324 patients. Its main IPF efficacy result is still unproven, leaving investors exposed to a major clinical setback. (SEC)
Bristol Myers Squibb’s Phase 3 result also creates a competitive risk: its IPF drug may set a clinical and commercial benchmark before PIPE-791’s data arrive. Contineum will need to show that its candidate can compete, even though the peer’s higher dose did not meet statistical significance. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
CTNM Financial Performance
Revenues and expenses
CTNM Earnings Performance
Company profitability
Upcoming events
No upcoming events
CTNM News
AllArticlesVideos
Funds containing CTNM
Fund name | Fund size | $CTNM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.